Mostrar el registro sencillo del ítem

dc.contributor.authorde Gonzalo-Calvo, David
dc.contributor.authorMartinez-Camblor, Pablo
dc.contributor.authorBelmonte, Thalia
dc.contributor.authorBarbé, Ferran
dc.contributor.authorDuarte, Kevin
dc.contributor.authorCowie, Martin R.
dc.contributor.authorAngermann, Christiane E.
dc.contributor.authorKorte, Andrea
dc.contributor.authorRiedel, Isabelle
dc.contributor.authorLabus, Josephine
dc.contributor.authorKoenig, Wolfgang
dc.contributor.authorZannad, Faiez
dc.contributor.authorThum, Thomas
dc.contributor.authorBär, Christian
dc.date.accessioned2024-04-10T01:40:05Z
dc.date.available2024-04-10T01:40:05Z
dc.date.issued2023
dc.identifier10.1186/s12967-023-04558-w
dc.identifier.issn14795876
dc.identifier.urihttps://hdl.handle.net/20.500.12728/10657
dc.description.abstractBackground: Patients with heart failure with reduced ejection fraction (HFrEF) and central sleep apnea (CSA) are at a very high risk of fatal outcomes. Objective: To test whether the circulating miRNome provides additional information for risk stratification on top of clinical predictors in patients with HFrEF and CSA. Methods: The study included patients with HFrEF and CSA from the SERVE-HF trial. A three-step protocol was applied: microRNA (miRNA) screening (n = 20), technical validation (n = 60), and biological validation (n = 587). The primary outcome was either death from any cause, lifesaving cardiovascular intervention, or unplanned hospitalization for worsening of heart failure, whatever occurred first. MiRNA quantification was performed in plasma samples using miRNA sequencing and RT-qPCR. Results: Circulating miR-133a-3p levels were inversely associated with the primary study outcome. Nonetheless, miR-133a-3p did not improve a previously established clinical prognostic model in terms of discrimination or reclassification. A customized regression tree model constructed using the Classification and Regression Tree (CART) algorithm identified eight patient subphenotypes with specific risk patterns based on clinical and molecular characteristics. MiR-133a-3p entered the regression tree defining the group at the lowest risk; patients with log(NT-proBNP) ≤ 6 pg/mL (miR-133a-3p levels above 1.5 arbitrary units). The overall predictive capacity of suffering the event was highly stable over the follow-up (from 0.735 to 0.767). Conclusions: The combination of clinical information, circulating miRNAs, and decision tree learning allows the identification of specific risk subphenotypes in patients with HFrEF and CSA. © 2023, BioMed Central Ltd., part of Springer Nature.es_ES
dc.description.sponsorshipIRBLleida; de Catalunya; ResMed; European Commission, EC, (PI20/00577); Deutsche Forschungsgemeinschaft, DFG, (TRR267 Project-ID 403584255-TRR 267); Instituto de Salud Carlos III, ISCIII, (CP20/00041)es_ES
dc.language.isoenes_ES
dc.publisherBioMed Central Ltdes_ES
dc.subjectBiomarkeres_ES
dc.subjectCentral sleep apneaes_ES
dc.subjectDecision tree learninges_ES
dc.subjectHeart failurees_ES
dc.subjectMachine learninges_ES
dc.subjectmicroRNAes_ES
dc.subjectReduced ejection fractiones_ES
dc.subjectSERVE-HFes_ES
dc.titleCirculating miR-133a-3p defines a low-risk subphenotype in patients with heart failure and central sleep apnea: a decision tree machine learning approaches_ES
dc.typeArticlees_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem